Research Associate II/ Associate Scientist I, Preclinical Pharmacology

Preclinical Pharmacology Cambridge, MA


What’s in it for you?

We are seeking a highly motivated individual who thrives in a dynamic, fast-paced, team-oriented and collaborative environment to be part of our success in the preclinical pharmacology group.

The successful candidate is expected to perform in vivo experiments in the area of heart failure, lung  and kidney diseases, but also to perform sample collections for biomarker studies and target engagement determination and related endpoint analysis, and contribute to genotyping, and in vitro experiments including QPCR, ELISA, MSD….

A proven track record of use of in vivo disease models in rodent species and conducting studies to evaluate efficacy and mechanism of action of potential therapeutic agents is critical. The candidate must have strong written and oral communication skills, be self-motivated, a team player and able to work independently.

What will you be doing?

  • Perform experiments to evaluate efficacy and mechanism of action of protein therapeutic agents in models of cardiac, lung and kidney diseases
  • Hands on capabilities working with rodents, in depth knowledge of in vivo model systems and familiarity with molecular and cell biology experiments.
  • Proven experience in surgical skills preferably pulmonary, renal, or cardiac small surgery in mice and rats.
  • Collect, archive and organize samples for downstream analysis.
  • Deliver reproducible results under aggressive timelines.
  • Work with cross functional drug development group to bring research stage molecules to clinical development.
  • Prepare, present and review scientific presentations for internal/external use.

What are we looking for?

  • BS degree with 2-5 years or MS degree with 2+ years of academic or industrial experience in animal model development.
  • Excellent rodent handling, injection, surgery, and necropsy skills.
  • Able to work independently on design and implementation of experiments.
  • Ability to prioritize responsibilities to meet project deadlines.
  • Prior experience in models of organ fibrosis.

How will you grow with us?

You will have an exciting opportunity as a member of our preclinical pharmacology team to significantly contribute to multiple programs. Our team collaborates with the various teams within preclinical pharmacology as well as translational and exploratory biology, bioanalytical development and more. This opportunity will allow you to work on a supportive team that is focused on passion, inquiry, and fun. Join our group today!

*Recruiters - please do not send unsolicited resumes to this posting.



Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair. Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) next year. In hematology, REBLOZYL® (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis. For more information, please visit Follow Acceleron on Social Media: @AcceleronPharma and LinkedIn.